@article{ArendtReinhardtImjelaSchulteetal.2021,
  author    = {Arendt, Robert and Reinhardt-Imjela, Christian and Schulte, Achim and Faulstich, Leona and Ullmann, Tobias and Beck, Lorenz and Martinis, Sandro and Johannes, Petrina and Lengricht, Joachim},
  title     = {Natural pans as an important surface water resource in the Cuvelai Basin — Metrics for storage volume calculations and identification of potential augmentation sites},
  series = {Water},
  volume    = {13},
  journal   = {Water},
  number    = {2},
  issn      = {2073-4441},
  doi       = {10.3390/w13020177},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223019},
  year      = {2021},
  abstract  = {Numerous ephemeral rivers and thousands of natural pans characterize the transboundary Iishana-System of the Cuvelai Basin between Namibia and Angola. After the rainy season, surface water stored in pans is often the only affordable water source for many people in rural areas. High inter- and intra-annual rainfall variations in this semiarid environment provoke years of extreme flood events and long periods of droughts. Thus, the issue of water availability is playing an increasingly important role in one of the most densely populated and fastest growing regions in southwestern Africa. Currently, there is no transnational approach to quantifying the potential storage and supply functions of the Iishana-System. To bridge these knowledge gaps and to increase the resilience of the local people's livelihood, suitable pans for expansion as intermediate storage were identified and their metrics determined. Therefore, a modified Blue Spot Analysis was performed, based on the high-resolution TanDEM-X digital elevation model. Further, surface area-volume ratio calculations were accomplished for finding suitable augmentation sites in a first step. The potential water storage volume of more than 190,000 pans was calculated at 1.9 km\(^3\). Over 2200 pans were identified for potential expansion to facilitate increased water supply and flood protection in the future.},
  language  = {en}
}
@article{TappenbeckSchroederNiebergallRothetal.2019,
  author    = {Tappenbeck, Nils and Schr{\"o}der, Hannes M. and Niebergall-Roth, Elke and Hassinger, Fathema and Dehio, Ulf and Dieter, Kathrin and Kraft, Korinna and Kerstan, Andreas and Esterlechner, Jasmina and Frank, Natasha Y. and Scharffetter-Kochanek, Karin and Murphy, George F. and Orgill, Dennis P. and Beck, Joachim and Frank, Markus H. and Ganss, Christoph and Kluth, Mark A.},
  title     = {In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials},
  series = {Cytotherapy},
  volume    = {21},
  journal   = {Cytotherapy},
  doi       = {10.1016/j.jcyt.2018.12.005},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240456},
  pages     = {546-560},
  year      = {2019},
  abstract  = {Background aims Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5+ MSCs) represent a promising candidate for stem cell-based therapy of various currently uncurable diseases in several fields of regenerative medicine. We have developed and validated a method to isolate, from human skin samples, and expand ABCB5+ MSCs that meet the guideline criteria of the International Society for Cellular Therapy. We are able to process these cells into a Good Manufacturing Practice-conforming, MSC-based advanced-therapy medicinal product. Methods To support the development of ABCB5+ MSCs for potential therapeutic topical, intramuscular and intravenous administration, we have tested our product in a series of Good Laboratory Practice-compliant nonclinical in-vivo studies addressing all relevant aspects of biosafety, including potential long-term persistence and proliferation, distribution to nontarget tissues, differentiation into undesired cell types, ectopic tissue formation, tumor formation and local tissue reaction. Results (i) Subcutaneous application of 1 × 107 ABCB5+ MSCs/animal and intravenous application of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice did not result in safety-relevant biodistribution, persistence or proliferation of the cells; (ii) three monthly subcutaneous injections of ABCB5+ MSCs at doses ranging from 1 × 105 to 1 × 107 cells/animal and three biweekly intravenous injections of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice were nontoxic and revealed no tumorigenic potential; and (iii) intramuscular injection of 5 × 106 ABCB5+ MSCs/animal to immunocompromised mice was locally well tolerated. Discussion The present preclinical in vivo data demonstrate the local and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5+ MSCs.},
  language  = {en}
}